Bosutinib (SKI-606) 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
Bosutinib (SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.
More Information Supplier PageBosutinib (SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.
More Information Supplier PageBosutinib (SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.
More Information Supplier PageBosutinib (SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.
More Information Supplier PageBortezomib is a highly selective, reversible inhibitor of the 26S proteasome
More Information Supplier PageBortezomib is a highly selective, reversible inhibitor of the 26S proteasome
More Information Supplier PageBortezomib is a highly selective, reversible inhibitor of the 26S proteasome
More Information Supplier PageBortezomib is a highly selective, reversible inhibitor of the 26S proteasome
More Information Supplier PageBortezomib is a highly selective, reversible inhibitor of the 26S proteasome
More Information Supplier PageBosutinib (SKI-606) is a tyrosine kinase inhibitor undergoing research for use in the treatment of cancer.
More Information Supplier PageBrivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
More Information Supplier Page